Detecting germline PTEN mutations among at-risk patients with cancer: An age- and sex-specific cost-effectiveness analysis

Journal of Clinical Oncology

Volumn 33, Issue 23, 2015, Pages 2537-2544

  Ngeow, Joanne ^a,c,d   Liu, Chang ^d   Zhou, Ke ^d   Frick, Kevin D ^e   Matchar, David B ^d   Eng, Charis ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CLEVELAND CLINIC SCORE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FIRST DEGREE RELATIVE; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; SEX DIFFERENCE; CONGENITAL TUMOR; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; GENETICS; HEALTH SURVEY; NEOPLASM; UNITED STATES;

ADULT; AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; GENETIC TESTING; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; PTEN PHOSPHOHYDROLASE; UNITED STATES;

EID: 84940393587     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.3456     Document Type: Article

References (38)

1. US Department of Health and Human Services: Healthy People 2020. Washington, DC, Office of Disease Prevention and Health Promotion. www.healthypeople.gov/2020/topics-objectives/topic/genomics
2. American Cancer Society: Cancer Facts & Figures 2014. http://www.cancer.org/Research/CancerFactsStatistics/CancerFactsFigures2014/cancer-facts-and-figures-2014.pdf
3. Tan MH, Mester J, Peterson C, et al: A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 88:42-56, 2011
4. Ngeow J, Mester J, Rybicki LA, et al: Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 96:E2063-E2071, 2011
5. Tan MH, Mester JL, Ngeow J, et al: Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400-407, 2012
6. Ngeow J, Stanuch K, Mester JL, et al: Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 32:1818-1824, 2014
7. Eng C: Will the real Cowden syndrome please stand up: Revised diagnostic criteria. J Med Genet 37:828-830, 2000
8. Foca F, Mancini S, Bucchi L, et al: Decreasing incidence of late-stage breast cancer after the introduction of organized mammography screening in Italy. Cancer 119:2022-2028, 2013
9. Chandra A, Martinez GM, Mosher WD, et al: Fertility, family planning, and reproductive health of US women: Data from the 2002 National Survey of Family Growth. Vital Health Stat 23:40, 2005
10. Mathews T, Hamilton BE: Mean age of mother, 1970-2000. Natl Vital Stat Rep 51:1-14, 2002
11. Dinh TA, Rosner BI, Atwood JC, et al: Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prevention Research 4:9-22, 2011
12. Wang H, Kåresen R, Hervik A, et al: Mammography screening in Norway: Results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control 12:39-45, 2001
13. Arveux P, Wait S, Schaffer P: Building a model to determine the cost-effectiveness of breast cancer screening in France. Eur J Cancer Care 12:143-153, 2003
14. Okonkwo QL, Draisma G, der Kinderen A, et al: Breast cancer screening policies in developing countries: A cost-effectiveness analysis for India. J Natl Cancer Inst 100:1290-1300, 2008
15. de Gelder R, Bulliard JL, de Wolf C, et al: Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer 45:127-138, 2009
16. Woo PP, Kim JJ, Leung GM: What is the most cost-effective population-based cancer screening program for Chinese women? J Clin Oncol 25:617-624, 2007
17. Siegel JE, Weinstein MC, Russell LB, et al: Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1339-1341, 1996
18. Torrance GW, Siegel JE, Luce BR: Framing and designing the cost-effectiveness analysis, in Gold MR, Siegel JE, Russell LB, et al (eds): Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996, p 65
19. Siegel JE, Weinstein MC, Torrance GW: Reporting cost-effectiveness studies and results, in Gold MR, Siegel JE, Russell LB, et al (eds): Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996, pp 285-287
20. van Hees F, Habbema JD, Meester RG, et al: Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med 160:750-759, 2014
21. Neumann PJ, Cohen JT, Weinstein MC: Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371:796-797, 2014
22. Briggs AH, Goeree R, Blackhouse G, et al: Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastro-esophageal reflux disease. Med Decis Making 22:290-308, 2002
23. Weinstein MC, Siegel JE, Gold MR, et al: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276:1253-1258, 1996
24. de la Chapelle A, Palomaki G, Hampel H: Identifying Lynch syndrome. Int J Cancer 125:1492-1493, 2009
25. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al: Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 357:165-168, 2001
26. Ladabaum U, Wang G, Terdiman J, et al: Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Ann Intern Med 155:69-79, 2011
27. Maciosek MV, Coffield AB, Edwards NM, et al: Priorities among effective clinical preventive services: Results of a systematic review and analysis. Am J Prev Med 31:52-61, 2006
28. Grosse SD, Teutsch SM, Haddix AC: Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health 28:365-391, 2007
29. Bond M, Pavey T, Welch K, et al: Systematic review of the psychological consequences of false-positive screening mammograms. Health Technol Assess 17:1-170, v-vi, 2013
30. Bull AR, Cambell MJ: Assessment of the physiological impact of a breast screening programme. Br J Radiol 64:510-515, 1991
31. Ellman R, Angeli N, Christians A, et al: Psychiatric morbidity associated with screening for breast cancer. Br J Cancer 60:781-784, 1989
32. Ong G, Austoker J, Brett J: Breast screening: Adverse psychological consequences one month after placing women on early recall because of a diagnostic uncertainty. A multicentre study. J Med Screen 4:158-168, 1997
33. Ekeberg Ø, Skjauff H, Kåresen R: Screening for breast cancer is associated with a low degree of psychological distress. The Breast 10:20-24, 2001
34. Gram IT, Lund E, Slenker SE: Quality of life following a false positive mammogram. Br J Cancer 62:1018-1022, 1990
35. Hobert JA, Embacher R, Mester JL, et al: Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly. Eur J Hum Genet 22:273-276, 2014
36. Butler MG, Dasouki MJ, Zhou XP, et al: Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42:318-321, 2005
37. Mester JL, Tilot AK, Rybicki LA, et al: Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet 19:763-768, 2011
38. Pal A, Barber TM, Van de Bunt M, et al: PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med 367:1002-1011, 2012